About This Report
Reporting Period The reporting period for this report is January 1, 2025, to December 31, 2025, with reference to previous important years as necessary.
Reporting Scope This report is based on CR BOYA-BIO Pharmaceutical Group Co., Ltd. as the main entity, including its subordinate subsidiaries. Unless otherwise specified, the scope of this report is consistent with the company's annual report.
Basis of Preparation
- "Guiding Opinions on High-Standard Fulfillment of Social Responsibilities by Central Enterprises in the New Era" and "Research on ESG Special Reporting for Central Enterprise-Controlled Listed Companies" issued by the State-owned Assets Supervision and Administration Commission of the State Council.
- "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 17 — Sustainability Report (Trial)", "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 2 — Norms for Operation of GEM Listed Companies (2025 Revision)", and "Shenzhen Stock Exchange GEM Listed Company Self-Regulatory Supervision Guidelines No. 3 — Sustainability Report Preparation (2026 Revision)" issued by the Shenzhen Stock Exchange.
- "China Enterprise Sustainable Development Report Guidelines" (CASS-ESG 6.0) issued by the China Enterprise Reform and Development Research Society.
- "Guidelines for Social Responsibility Reporting" (GB/T 36001-2015) issued by the Standardization Administration of China.
- "Global Reporting Initiative (GRI) Standards" issued by the Global Reporting Initiative (GRI).
- "United Nations Sustainable Development Goals" (SDGs).
Reporting Cycle This report is an annual report and is the fifth ESG/Social Responsibility Report issued by CR BOYA-BIO Pharmaceutical Group Co., Ltd.
Data Sources All information and data cited in this report are from internal documents of CR BOYA-BIO Pharmaceutical Group Co., Ltd. or relevant public information.
Reporting Commitment CR BOYA-BIO guarantees that the content of this report contains no false records, misleading statements, or significant omissions.
Terminology CR BOYA-BIO, the Company, Company, We: refers to CR BOYA-BIO Pharmaceutical Group Co., Ltd. CR Group, Group: refers to China Resources (Holdings) Co., Ltd. CR Pharma: refers to CR Pharma Co., Ltd. Xinbai Pharmaceutical: refers to Nanjing Xinbai Pharmaceutical Co., Ltd. Green Cross (China): refers to Green Cross (China) Pharmaceutical Co., Ltd.
Accessibility This report is publicly released in both printed and PDF electronic formats. To obtain the electronic version, please visit the official website of CR BOYA-BIO (https://www.china-boya.com) or download and browse it on Cninfo.com.cn (http://www.cninfo.com.cn).
Table of Contents
CONTENTS
Special Topic: Party Building Inspires the Heart 16
- Strengthening Theoretical Armament 16
- Consolidating Grassroots Party Building 18
- Deep Integration of Party Building and Business 18
- Comprehensive and Strict Governance of the Party 20
Special Topic: Practicing Mission with Actions 22
- Warm Care 22
- Public Welfare and Education 24
- Joint Construction 25
Upholding the Green Mountains and Steadfastly Moving Forward 26
- Climate Change 28
- Low-Carbon Operations 31
Long-Term Efforts Lead to Gradual Achievement 38
- Ingenious Operations 40
- Mutual Benefit and Win-Win 55
Gathering Strength to Ignite the Flame 58
- Moving Forward Together 60
- Warmth and Strength 75
Following the Right Path to Innovate and Renew 78
- Standardized Governance 80
- Sincere and True 82
Outlook 87 Appendix 88
- Key Performance Indicators 88
- Index of Indicators 91
- Feedback Form 93